Torbay Holdings Inc: Pilot-Scale Study Published Into the Impact of the AirO2bic Mouse Upon Median Nerve Conduction Velocity: A Diagnostic For Carpal Tunnel Syndrome

Torbay Holdings, Inc. (OTC BB: TRBY) announces that the pilot-scale clinical study as to the potential impact of the AirO2bic mouse's "Functional Neutral" posture upon Median Nerve Conduction in relation to Carpal Tunnel Syndrome (CTS) has now been posted to the aerobicmouse website (link below).

The study, commissioned by Designer Appliances, Inc. was conducted at Brevhard Rehabilitation Medicine, a diagnostic and therapy clinic in Florida.

The objective TRBY sought was to investigate the possibility of using a clinically diagnostic test for Carpal Tunnel Syndrome, such as Nerve Conduction Velocity (NCV) testing is, to determine if any noticeable impact of switching to the AirO2bic mouse could be detected as a change in a subject's median nerve conduction. CTS is associated with a swelling in the wrist that can lead to nerve entrapment impacting the speed at which nerve impulses travel down the arm, traveling more slowly when the nerve becomes entrapped.

The 3-month pilot-scale study was on a sample of computer mouse users who had not previously been measured by NCV or had been diagnosed as having CTS. TRBY's synopsis of the report: -

1. Some 40% of the subjects (mouse users of 6-8 hours or more per working day) were diagnosable as having CTS based upon the initial NCV measurement taken at the start of the study.

2. A measurable affect was detected in median nerve conduction velocity after switching to the AirO2bic mouse over the course of the 3-month study period.

3. The affect detected was "positive" as all participants experienced varying degrees of improvement in their median nerve conduction.

4. All but one subject were back within the normal range by the end of the study, though the outlier subject was at the diagnostic threshold for one parameter and had seen significant reduction in both parameters measured.

5. There was no negative impact of using the AirO2bic measured by NCV, in fact an improvement in "normal" subjects NCV readings was seen, which placed them further into the normal range, or put another way, further away from the clinical diagnostic threshold for CTS.

Tom Large, President & CEO, stated: "We have carefully considered these data with respect to any conclusions that we may draw. This is the first small study of its kind and we are mindful of the impact that this and future studies may have upon mouse usage, especially in light of the revelation as to product liability in the legal opinion recently received. But, as with all new discoveries, we believe it is important to report upon it as it fuels the CTS debate and may encourage further parallel studies that look at clinical markers, by which people are diagnosed and not just at product comfort estimates after a few hours of mouse use, which appears to be the journalistic norm. The computer mouse is fundamental to the method of work and recreation in our computerized society. It even has Law associated with it, though this study suggests a circumstance beyond that anticipated by that law, the potential for a correlation between a Section 508 [asserted] compliant mouse design and Carpal Tunnel Syndrome remediation. As we have stated repeatedly, if you design to make input devices more accessible to those with disability or impairment (which is the stated objective of Section 508 Law) then you reduce the need to use those muscle or nerves that may be less capable of coordination. So the use of that same design by those without such disability may have the potential to reduce the consequences of mouse overuse by not employing those muscles and nerves that may be prone to injury and impairment due to extensive computer mouse use. We believe that this is truly Universal Design and that the results of this study are indicative of the convergence of our theory and practice"

TRBY believes that these data obtained are important and significant to its business as they are in support of its claims as to a belief in the benefits of its AirO2bic mouse design, and this study further correlates with reported user experience (that inspired the commissioning of this study) that the use of the AirO2bic mouse helped towards a remediation of their Carpal Tunnel Syndrome symptoms.

Tom Large, President & CEO, went on to say: "What we find significant is that the data from NCV 'normal' subjects showed improvement and their values headed away from the clinically diagnostic CTS threshold. It is reasonable to expect that CTS develops slowly and there is a gradual deterioration of the wrist that eventually results in a clinically diagnostic NCV reading being seen. It is important to improve the CTS condition once it occurs, but if, as this data might suggest, it is possible to reverse the impact of mouse use, before CTS becomes clinically discernable, then that might have a significant impact upon mouse associated CTS and could potentially save Government. Industry and Health Insurers the billions of dollars attributed by others as to the cost of CTS impairment; to say nothing of the potential for the relief of pain and misery that that CTS inflicts upon thousands of computer mouse users daily."

The report was co-authored by Dr. S. Millar of Brevhard Rehabilitation Medicine and Tom Large, President & CEO, who qualified and practiced in the pathological sciences, majoring in clinical biochemistry and is published in his own right.

Designer Appliances, Inc. is leading the way in the development of Anti.Fatigue(TM) tools and technologies to manage the impact that fatigue is now understood to have upon computer users. Anti.Fatigue(TM) design conforms to Universal Design criteria so produces products that are more "Accessible and Assistive" to all, including persons with dexterity impairment or disability. We are all capable of fatigue.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this release that are not historical, are forward-looking statements that are subject to risks and uncertainties that could cause results to differ materially from those expressed in the forward-looking statements, including but not limited to, certain delays and risks detailed from time to time in the company's filings with the Securities and Exchange Commission.

CTS Study Link: www.aerobicmouse.com/AirO2bic_Mouse_CTS_Study.pdf

Legal Opinion Letter: http://www.aerobicmouse.com/pdf/LegalOpinion.pdf

Distributed by Market Wire